MOLECULAR-GENETIC CRITERIA AND PROSPECTIVE BIOMARKERS OF SERRATED ADENOMAS OF COLORECTAL LOCALIZATION
Abstract
A retrospective analysis of the database of patients with histologically verified serrated adenomas of the colon was carried out as part of an observational study. Inclusion criteria: patients with serrated colon adenomas who underwent a molecular genetic study to detect mutations and further sequencing 16 sRNAs of intestinal microbiota from January 2021 to October 2021. The exclusion criteria: patients with a primary tumor of the colon who had previously received complex treatment, who had accompanying pathologies of the other organs and systems, which did not allow for the planned examination. According to the results of the study, BRAF mutations are diagnosed in half of the cases in serrated adenomas and in one-third of cases - KRAS mutations. As a result of a comparative analysis of the intestinal microbiome of young patients with serrated colon adenomas with summary statistical data on the presence of bacteria in the intestines of people from the Russian population; promising markers were found for the development of effective approaches for the early diagnosis of colorectal cancer.
References
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–12. Doi:10.3322/caac.21492.
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020; 70:7–30. doi:10.3322/caac.21590.
Day DW. The adenoma-carcinoma sequence. Scand J Gastroenterol Suppl. 1984;104:99–107.
Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007; 50:113–130. doi:10.1111/j.1365-2559.2006.02549.x.
Ng SC, Ching JY, Chan VC, et al. Association between serrated polyps and the risk of synchronous advanced colorectal neoplasia in average-risk individuals. Aliment Pharmacol Ther. 2015; 41:108– 115. doi:10.1111/apt.13003.
Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. The Lancet. 2019; 394:1467–1480. doi:10.1016/s0140-6736(19)32319-0.
Nagtegaal ID, Odze RD, Klimstra D et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020; 76:182–188. doi:10.1111/his.13975.
East JE, Atkin WS, Bateman AC, et al. British society of gastroenterology position statement on serrated polyps in the colon and rectum. Gut. 2017; 66(7):1181–1196. doi:10.1136/gutjnl-2017-314005.
Peters BA, Dominianni C, Shapiro JA, et al. The gut microbiota in conventional and serrated precursors of colorectal cancer. Microbiome. 2016; 4:69. doi:10.1186/s40168-016-0218-6.
Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, et al. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep. 2015; 16:164– 177. doi:10.15252/embr.201439263.
Rezasoltani S, Asadzadeh Aghdaei H, Dabiri H, et al. The association between fecal microbiota and different types of colorectal polyp as precursors of colorectal cancer. Microb Pathog. 2018; 124:244–249. doi:10.1016/j.micpath.2018.08.035.
Yoon H, Kim N, Park JH, et al. Comparisons of gut microbiota among healthy control, patients with conventional adenoma, sessile serrated adenoma, and colorectal cancer. J Cancer Prev. 2017; 22:108–114. doi:10.15430/JCP.2017.22.2.108.
Lee DW, Han SW, Kang JK, et al. Association between fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Ann Surg Oncol. 2018; 25:3389–3395. doi:10.1245/s10434-0186681-5.
Yu J, Chen Y, Fu X, et al. Invasive fusobacterium nucleatum may play a role in the carcinogenesis of proximal colon cancer through the serrated neoplasia pathway. Int J Cancer. 2016; 139:1318–1326. doi:10.1002/ijc.30168.
Ito M, Kanno S, Nosho K, et al. Association of fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer. 2015; 137:1258–1268. doi:10.1002/ijc.29488.
Park CH, Han DS, Oh YH, et al. Role of Fusobacteria in the serrated pathway of colorectal carcinogenesis. Sci Rep. 2016; 6:25271. doi:10.1038/srep25271
K. Stefanius, L. Ylitalo, A. Tuomisto et al., Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. Histopathology. 2011; 58(5):679–692. doi:10.1111/j.1365-2559.2011.03821.x
M. J. O'Brien, S. Yang, C. Mack et al., Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points The American Journal of Surgical Pathology. 2006; 30(12):1491–1501.
CC BY-ND
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.
